The tweet was deleted by the author.
But we saved everything 🙂.
NeoGenomics has unveiled its latest MRD solution, RaDaR ST, at the 2025 ESMO Congress.
This addition bolsters their pharma services test menu and highlights their commitment to advancing medical diagnostics. The ESMO Congress is regarded as a pivotal platform for showcasing cutting-edge oncology developments. NeoGenomics, a prominent player in genetic testing, is set to leverage RaDaR ST capabilities to enhance the precision of tracking residual disease in patients, thus improving treatment outcomes.
NeoGenomics' strategic expansion into MRD solutions with RaDaR ST closely follows its pioneering work in spatial proteomics, exemplified by the launch of Paletrra. Together, these advances underscore the company's ongoing efforts to integrate innovative diagnostics across oncology, reinforcing its leadership amid a rapidly evolving therapeutic landscape.